LivaNova (NASDAQ:LIVN) CFO Alex Shvartsburg Sells 2,500 Shares of Stock

LivaNova PLC (NASDAQ:LIVN) CFO Alex Shvartsburg sold 2,500 shares of the business’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $90.91, for a total value of $227,275.00. Following the completion of the transaction, the chief financial officer owned 42,147 shares in the company, valued at $3,831,583.77. This trade represents a 5.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

LivaNova Stock Up 1.2%

LIVN stock traded up $1.12 during mid-day trading on Friday, hitting $91.32. The stock had a trading volume of 742,276 shares, compared to its average volume of 743,907. The company has a current ratio of 1.46, a quick ratio of 1.22 and a debt-to-equity ratio of 0.22. LivaNova PLC has a 1-year low of $52.37 and a 1-year high of $99.38. The company has a fifty day moving average of $80.12 and a 200 day moving average of $74.09. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of 30.44 and a beta of 0.91.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17. The company had revenue of $393.15 million during the quarter, compared to the consensus estimate of $381.13 million. LivaNova had a return on equity of 16.10% and a net margin of 13.01%. The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period last year, the business earned $1.11 EPS. On average, equities analysts expect that LivaNova PLC will post 3.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LIVN has been the topic of several recent research reports. Needham & Company LLC raised their price objective on shares of LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Zacks Research downgraded shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Mizuho set a $115.00 price target on shares of LivaNova in a research note on Wednesday, November 4th. Jefferies Financial Group restated a “buy” rating on shares of LivaNova in a report on Wednesday, November 4th. Finally, Barclays raised their price target on shares of LivaNova from $105.00 to $120.00 and gave the company an “overweight” rating in a report on Monday. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $101.22.

Institutional Trading of LivaNova

Several large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its holdings in shares of LivaNova by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock worth $116,067,000 after buying an additional 38,320 shares during the period. Janus Henderson Group PLC raised its holdings in LivaNova by 1,978.8% in the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after acquiring an additional 448,703 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in LivaNova in the 1st quarter worth $18,327,000. Sei Investments Co. raised its holdings in LivaNova by 56.6% in the 1st quarter. Sei Investments Co. now owns 218,805 shares of the company’s stock worth $13,907,000 after acquiring an additional 79,088 shares during the period. Finally, Renaissance Technologies LLC lifted its position in LivaNova by 15.7% during the 1st quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock worth $11,631,000 after acquiring an additional 24,900 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.